HighPoint Advisor Group’s Novo Nordisk NVO Stock Holding History

HighPoint Advisor Group’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$521K	Buy	10,863 +2,576	+31%	+$111K	0.02%	457
2026 Q1	$305K	Sell	8,287 -21,792	-72%	-$1.03M	0.01%	530
2025 Q4	$1.53M	Buy	30,079 +10,165	+51%	+$520K	0.03%	369
2025 Q3	$1.11M	Buy	19,914 +503	+3%	+$29.4K	0.05%	247
2025 Q2	$1.34M	Sell	19,411 -28	-0.1%	-$1.91K	0.07%	210
2025 Q1	$1.27M	Buy	19,439 +91	+0.5%	+$7.52K	0.07%	210
2024 Q4	$1.62M	Buy	19,348 +841	+5%	+$90.9K	0.09%	180
2024 Q3	$2.07M	Sell	18,507 -266	-1%	-$35.5K	0.12%	141
2024 Q2	$2.43M	Buy	18,773 +297	+2%	+$39.4K	0.14%	118
2024 Q1	$2.45M	Buy	18,476 +346	+2%	+$41.2K	0.17%	104
2023 Q4	$2.34M	Buy	+18,130	New	+$1.79M	0.17%	107

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

HighPoint Advisor Group's NVO Position: Q2 2026 in Review

HighPoint Advisor Group increased its Novo Nordisk (NVO) stake by 31% in Q2 2026, buying an estimated $111K and bringing the position to 10,863 shares worth $521K. The position accounts for 0.02% of the portfolio, ranked #457.

HighPoint Advisor Group first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.45M in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

HighPoint Advisor Group held 10,863 shares of Novo Nordisk worth $521K as of Q2 2026.
HighPoint Advisor Group bought 2,576 Novo Nordisk shares in Q2 2026, an estimated $111K.
Novo Nordisk made up 0.02% of HighPoint Advisor Group's portfolio in Q2 2026, its #457 holding.
HighPoint Advisor Group first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
HighPoint Advisor Group's Novo Nordisk position peaked at $2.45M in Q1 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on HighPoint Advisor Group's 13F filing for Q2 2026, filed 5 Aug 2026.